Audit: QRS - Yohimbine for Health & Longevity

Audit conducted on 22/09/2026 19:49 using AI4L + evidence-mcp / Opus 5

Iterations

Summary

Items Count
Total 94
Passed 85
Failed 0
N/A 9
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All protocol doses (5.4 mg three times daily; ~0.2 mg/kg fasted), gate items, tiered benefits/risks, biomarker rows and qualitative markers trace to ER Therapeutic Protocol, Key Interactions & Contraindications, Expected Benefits, Potential Risks & Side Effects and Monitoring Protocol & Defining Success.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 E.g. time_2_sub “If it occurs at all” mirrors the ER’s “if they occur at all” (ER line 381).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 MAOIs, pregnancy/breastfeeding and the other ER “populations who should avoid” items stay in the Contraindications gate, not in Key Interactions.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Gates draw only from ER Key Interactions & Contraindications; no Benefit-Modifying Factors or Risk-Modifying Factors content is surfaced as a gate.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, NCT IDs, author names or brand names appear anywhere in the QRS.
1.6 The QRS does not introduce new attributions. 🟢 No attributions present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Matter-of-fact, evidence-weighted register identical to the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Tiered benefits/risks plus concrete doses, targets and cadence.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Protocols are described as historical/practitioner standards, not prescriptions.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Statements are descriptive (“Evening use is discouraged”), not directives to the reader.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 No “recommended”, “advised” or “should” constructions in the sheet’s own voice.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns anywhere in the file.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms appear only where the decision gates require precision (eGFR, Child-Pugh, PDE5 inhibitors); the lede is fully plain.
2.8 Information is presented in a concise and very compact manner 🟢 Single-clause gate items, semicolon-joined tier lists, 65-word lede.
2.9 It DOES NOT address the reader directly 🟢 Confirmed — no “you”/”your”.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Dose-by-weight, fasted-cardio timing and pre/post-dose self-monitoring assume a proactive user.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Fasted morning dosing before cardiovascular exercise and repeated blood-pressure checks are retained.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 No generic consumer framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Lede states the erection benefit is modest and the fat-loss and longevity cases thin/speculative, matching the ER Conclusion.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “longevity claims are speculative”; “anti-aging” does not occur.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 No colloquial route-of-administration or adverse-event wording; “difficulty getting an erection” is the ER’s own gloss (ER lines 37, 444).

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All headings, gate titles, tier labels and column headers are byte-identical to [qrs_template].
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 34 template variables present; the repeatable marker_#* and qualitative_item# spans are expanded to marker_1–4 and qualitative_item_1–5.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 The website=”evidence_review”, website=”audit” and website=”full_review” spans and all CSS are unchanged.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section that feeds the QRS is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels (“Erectile-dysfunction protocol (historical clinical standard)”, “Fat-loss protocol (fitness-practitioner standard)”, “Best time of day”) and all five Qualitative Assessment bold labels are verbatim ER labels.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Biomarker names are verbatim from the ER table; time-to-effect labels name the ER’s own aspects (erectile response, body-composition change, alertness and heart rate).
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji characters in the file.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Tier lines are collapsed into one list item per tier, gate items are single clauses, and the four-row biomarker table plus five qualitative lines stay within the one-page budget.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14, immediately after the doctype.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening “—” line 3, closing “—” line 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata values repeated on the page except the legitimate subline date/model.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:02" is quoted, which the colon requires.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: yohimbine_2026-0731-0101_Opus_ER.md (line 4).
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.9.22 matches the QRS.md version badge.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0922-1947.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 Single word “Opus”.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: yohimbine_2026-0731-0101_Opus_QRS.html matches the file on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified: all values trimmed, single space after each key.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “Yohimbine for Health & Longevity - Quick Reference Sheet” (line 22).
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “Yohimbine for Health & Longevity” (line 417).
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0922-1947 → “09/22/2026”.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 5”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header holds only the title and the template subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens “Yohimbine is a plant compound from West African tree bark, sold as a supplement for fat loss and alertness…” before any evidence verdict.
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Compresses the ER Conclusion (lines 442–444): modest erection benefit, thin fat-loss case, speculative longevity, cardiovascular/anxiety load, product variability.
7.3 [at_a_glance] is no longer than 70 words 🟢 65 words.
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each clause maps to a distinct ER passage in Motivation (line 37) and Conclusion (line 444).
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Uses “plant compound”, “difficulty getting an erection”; no acronyms.
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years or sample sizes.
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No odds ratios or percentages.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All eight items come from the MAOI bullet and the “Populations who should avoid yohimbine” bullet (ER lines 296, 312).
8.2 [stop_items] represent the Contraindications from the ER 🟢 Every population named in ER line 312 plus MAOIs is represented; none is omitted.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Eight <li> elements inside the span.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 The ER’s “— an older class of antidepressant” gloss and “Absolute contraindication…” rationale are stripped; no trailing dash clauses remain.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 ≥140/90 mmHg, eGFR <60 mL/min/1.73m², Child-Pugh Class B or C and the named MAOIs are all preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation in this section; “>”/”≥” appear only as numeric thresholds.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 The ER names such populations, and the section is correctly populated.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All seven items map to ER bullets on lines 298–310.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 All seven non-contraindicated interaction bullets are present; the MAOI bullet is correctly excluded and kept in the stop gate.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Seven <li> elements inside the span.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 All “Caution. … Mitigation: …” rationale and the “— drugs that lower blood pressure” gloss are stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Named examples are retained throughout (caffeine/synephrine/ephedrine/pseudoephedrine/amphetamines; amitriptyline/clomipramine; fluoxetine/sertraline; clonidine; sildenafil).
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation in this section.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 The ER names several interactions, and the section is correctly populated.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 All three cells come from the first three bullets of ER Therapeutic Protocol (lines 334–338).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Erectile-dysfunction regimen, fat-loss dose, and timing of dosing are the three decision-relevant aspects; the remaining bullets are modifiers.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER provides three or more actionable aspects; all three sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 Labels verbatim; values “5.4 mg three times daily” and “~0.2 mg/kg, fasted” match ER lines 334 and 336.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Erectile response, body-composition change, and alertness/heart rate — exactly the aspects in ER Practical Considerations line 381.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Order follows the ER benefit tiers: erectile function (Medium) → fat loss (Low) → alertness (Speculative).
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct aspects exist and all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 “Within an hour” / “Weeks” and the half-life sub-line (0.5–1 hour) match ER lines 340 and 381.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All six benefit headings from ER lines 154–192 are represented in their ER tiers.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Bare headings only; the “⚠️ Conflicted” flags and Magnitude lines are dropped.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses or odds ratios in the Benefits card.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 The ER has no High-tier benefit; benefits_high is emptied and set to style="display: none" (line 527).

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All eight risk headings from ER lines 219–274 appear in their ER tiers.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Headings only, semicolon-separated; all Magnitude lines dropped.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses in the Risk & Side Effects card.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A The ER populates all four risk tiers, so no span needs hiding.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Table rows and cadence come from ER Monitoring Protocol & Defining Success (lines 407–414).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All four ER biomarker rows (resting blood pressure, resting heart rate, fasting glucose, eGFR) are present with verbatim targets.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Pre/post-dose checks for 1–2 weeks, weekly for the first month, then every 3–6 months — matches ER line 407.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Taken from the qualitative-marker list at ER lines 418–422.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five ER qualitative markers are present with their bold labels verbatim.

Issues 22/09/2026 19:49

Pass rate 100.00%. No issues found.